Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and

Min Lv1, Shuying Ma, Yueli Tian

  • 1College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, Gansu Province, People's Republic of China. xyzhang@lzu.edu.cn.

Molecular Biosystems
|November 6, 2014
PubMed

Insights

This study reveals key molecular interactions for triazolone Chk1 inhibitors, showing hydrophobic groups enhance binding while hydrophilic groups hinder it. This guides the design of new cancer therapies targeting DNA damage response.

Area of Science:

  • Biochemistry
  • Computational Chemistry
  • Drug Discovery

Background:

  • Checkpoint kinase 1 (Chk1) is crucial in DNA damage signaling and a target for cancer therapy.
  • The precise mechanism of action for novel triazolone Chk1 inhibitors remains unclear.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying the bioactivity of triazolone Chk1 inhibitors.
  • To identify key structural features influencing triazolone inhibitory activity against Chk1.

Main Methods:

  • Integrated computational approach: molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations.
  • Comparative analysis using MK-8776, a clinical-stage Chk1 inhibitor, as a reference.
  • Detailed examination of inhibitor-protein interactions within the Chk1 binding pocket.

Main Results:

  • All studied inhibitors bind to a conserved pocket in Chk1 involving residues Leu14, Val22, Ala35, Glu84, Tyr85, Cys86, and Leu136.
  • Hydrophobic group introduction at R1 enhances Chk1 binding affinity, particularly interacting with Leu136.
  • A hydrogen bond between R1 and Cys86 aids inhibitor positioning, while hydrophilic groups at R2 decrease binding affinity.

Conclusions:

  • Hydrophobic modifications at R1 and avoidance of hydrophilic groups at R2 are critical for potent triazolone Chk1 inhibition.
  • Understanding these structure-activity relationships facilitates the rational design of novel, effective Chk1 inhibitors for cancer treatment.

Related Concept Videos

Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.0K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
10.6K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
11.8K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

1.8K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.4K